<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654886</url>
  </required_header>
  <id_info>
    <org_study_id>HS# 2013-9365</org_study_id>
    <nct_id>NCT02654886</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.</brief_title>
  <acronym>ExercisPompe</acronym>
  <official_title>Safety and Effectiveness of Resistance Exercise Training in Patients With Late Onset Pompe Disease- A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if exercise will help improve muscle
      strength, endurance, and quality of life in individuals with Pompe disease. This is a
      research study to further define the outcome of patients with Pompe disease treated with a
      combined diet and exercise therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility: Subjects that are age 16 years or older, have been diagnosed with Pompe disease
      by genetic testing, and are showing symptoms such as muscle weakness

      Time Commitment:

      The study will last for 8 months. This study consists of a baseline visit of and return
      visits at week 9, week 16, week 24, and week 32. At the week 9 visit the subject will be
      given an individualized exercise plan which will be carried out over the next 24 weeks. The
      subject will be asked to return for three more visits at week16, week 24 and week 32. The 24
      week training period will involve 3 workouts a week approximately 15-30 minutes each. It will
      also involve a breathing exercise that the subject can do at home twice daily for 10-15
      minutes per session. The study visits will include the exercise plan, physical exam, blood
      draw and questionnaires.

      Anticipated Benefits:

      The possible benefits include a delay in progression of muscle weakness. The knowledge gained
      from this study will help researchers understand the effect of exercise on the disease. This
      may eventually lead to new forms of prevention of symptom onset in the future.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Isometric muscle strength change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Inspiratory Pressures percent change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRC score change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle volume and texture change from week 8 through week 32 using MR Imaging</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycogen content change in quadriceps muscle from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAA enzyme activity change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HEX4 change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other spirometry parameters change from week 8 through week 32</measure>
    <time_frame>Eight months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pompe Disease</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Resistance Exercise Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resistance Exercise Training</intervention_name>
    <description>Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months
Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months</description>
    <arm_group_label>Resistance Exercise Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to fully consent to the protocol.

          2. Physically able to perform resistance exercises for 12 weeks.

          3. Patients with a confirmed diagnosis of Pompe disease.

          4. Age 16 years to 75 years.

          5. Currently receiving ERT.

          6. Patient on ERT for at least 1year.

        Exclusion Criteria:

          1. Patients with no confirmed diagnosis of Pompe disease, either by GAA enzyme deficiency
             from any tissue and/or molecular testing revealing two GAA gene mutations

          2. Unable to walk or cycle

          3. Unable to consent to the study/ procedures

          4. Women who are pregnant or breastfeeding

          5. Heart disease

          6. Patients with any metal inside their body such as metallic clips used for vascular
             repairs and/or implanted devices such as cardiac pacemakers which would prevent them
             from doing the MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Kimonis, MD MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abhilasha Surampalli, M.B.B.S.,</last_name>
    <phone>(949) 824-0521</phone>
    <email>asurampa@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Shambaugh</last_name>
    <phone>(949) 824-0521</phone>
    <email>cshambau@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCI ICTS (Institute for Clinical and Translational Science)</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhilasha Surampalli, M.B.B.S.,</last_name>
      <phone>949-824-0521</phone>
      <email>asurampa@uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis. 2010 Dec;33(6):727-35. doi: 10.1007/s10545-010-9201-8. Epub 2010 Sep 14.</citation>
    <PMID>20838899</PMID>
  </reference>
  <reference>
    <citation>Bodamer OA, Leonard JV, Halliday D. Dietary treatment in late-onset acid maltase deficiency. Eur J Pediatr. 1997 Aug;156 Suppl 1:S39-42. Review.</citation>
    <PMID>9266214</PMID>
  </reference>
  <reference>
    <citation>Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics. 2008 Oct;5(4):569-78. doi: 10.1016/j.nurt.2008.08.009. Review.</citation>
    <PMID>19019308</PMID>
  </reference>
  <reference>
    <citation>Slonim AE, Coleman RA, McElligot MA, Najjar J, Hirschhorn K, Labadie GU, Mrak R, Evans OB, Shipp E, Presson R. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology. 1983 Jan;33(1):34-8.</citation>
    <PMID>6401355</PMID>
  </reference>
  <reference>
    <citation>Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007 Jan;35(1):70-7.</citation>
    <PMID>17022069</PMID>
  </reference>
  <reference>
    <citation>Sveen ML, Jeppesen TD, Hauerslev S, KÃ¸ber L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008 Nov;131(Pt 11):2824-31. doi: 10.1093/brain/awn189. Epub 2008 Sep 6.</citation>
    <PMID>18776212</PMID>
  </reference>
  <reference>
    <citation>Terzis G, Dimopoulos F, Papadimas GK, Papadopoulos C, Spengos K, Fatouros I, Kavouras SA, Manta P. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 Nov;104(3):279-83. doi: 10.1016/j.ymgme.2011.05.013. Epub 2011 May 19.</citation>
    <PMID>21640624</PMID>
  </reference>
  <reference>
    <citation>Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol. 2004 Apr;55(4):495-502.</citation>
    <PMID>15048888</PMID>
  </reference>
  <reference>
    <citation>Jones HN, Crisp KD, Robey RR, Case LE, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining. Mol Genet Metab. 2016 Feb;117(2):120-8. doi: 10.1016/j.ymgme.2015.09.003. Epub 2015 Sep 8.</citation>
    <PMID>26381077</PMID>
  </reference>
  <reference>
    <citation>van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, Bussmann JB, van Doorn PA, van der Ploeg AT. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015 Jul 19;10:87. doi: 10.1186/s13023-015-0303-0.</citation>
    <PMID>26187632</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Virginia Kimonis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>Pompe disease</keyword>
  <keyword>Pompe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be made available to partcipants after data is published in a peer reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

